Estropipate
Low Testosterone, hypoestrogenism, moderate Vulvovaginal atrophy + 7 more
Treatment
13 FDA approvals
20 Active Studies for Estropipate
Treatment for
Low Testosterone
What is Estropipate
Estrone sulfate
The Generic name of this drug
Treatment Summary
Estrone sulfate (also known as estropipate) is a form of estrogen used to treat a variety of conditions, including menopause symptoms, infertility, underdeveloped female sexual characteristics, vaginal dryness, some types of breast cancer (particularly in men and postmenopausal women), prostate cancer, and osteoporosis.
Ogen
is the brand name
Estropipate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ogen
Estrone sulfate
1977
21
Approved as Treatment by the FDA
Estrone sulfate, also known as Ogen, is approved by the FDA for 13 uses including Hypogonadism and Postmenopausal Osteoporosis .
Hypogonadism
Postmenopausal Osteoporosis
Premature Ovarian Failure (POF)
Hot flashes
Premature Menopause
moderate Menopausal Vasomotor Symptoms
moderate Vulvovaginal atrophy
Low Testosterone
hypoestrogenism
Osteoporosis, Postmenopausal
Menopause
female castration
severe menopausal vulvovaginal atrophy
Effectiveness
How Estropipate Affects Patients
Estropipate is a type of estrogen, which is a hormone naturally produced by the body. Estrogens work by attaching to receptors in the body's cells. Estrogens also control the amount of two other hormones in the body, LH and FSH, which can be too high in postmenopausal women. Estropipate helps to reduce these high levels and bring them back to normal.
How Estropipate works in the body
Estradiol is a hormone that affects many parts of the body. It enters target cells and binds to a receptor, allowing it to enter the nucleus of the cell. The estradiol then causes genes to produce messenger RNA, which then creates proteins that bring about physical changes. Estradiol also stimulates the production of certain proteins in the liver, and reduces the amount of follicle-stimulating hormone in the pituitary gland.
When to interrupt dosage
The suggested dosage of Estropipate depends on the diagnosed condition, such as Menopause, Menopause and hypoestrogenism. The amount of dosage is contingent upon the type of delivery (e.g. Oral or Tablet, coated) specified in the table beneath.
Condition
Dosage
Administration
female castration
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Menopause
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
severe menopausal vulvovaginal atrophy
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Low Testosterone
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
hypoestrogenism
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
moderate Vulvovaginal atrophy
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Osteoporosis, Postmenopausal
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Premature Menopause
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
moderate Menopausal Vasomotor Symptoms
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Hot flashes
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Warnings
There are 20 known major drug interactions with Estropipate.
Common Estropipate Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Estrone sulfate.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Estrone sulfate.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Estrone sulfate.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Estrone sulfate.
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrone sulfate.
Estropipate Novel Uses: Which Conditions Have a Clinical Trial Featuring Estropipate?
39 active clinical trials are evaluating the potential of Estropipate to treat Low Testosterone, Hypoestrogenism and Moderate Menopausal Vasomotor Symptoms.
Condition
Clinical Trials
Trial Phases
female castration
0 Actively Recruiting
hypoestrogenism
1 Actively Recruiting
Phase 4
moderate Menopausal Vasomotor Symptoms
0 Actively Recruiting
moderate Vulvovaginal atrophy
0 Actively Recruiting
Premature Menopause
0 Actively Recruiting
Osteoporosis, Postmenopausal
0 Actively Recruiting
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Menopause
0 Actively Recruiting
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
severe menopausal vulvovaginal atrophy
0 Actively Recruiting
Estropipate Reviews: What are patients saying about Estropipate?
5
Patient Review
11/29/2007
Estropipate for Low Estrogen After Operation to Remove Ovaries
5
Patient Review
8/26/2014
Estropipate for Low Estrogen After Operation to Remove Ovaries
5
Patient Review
3/16/2009
Estropipate for "Change of Life" Signs
4.7
Patient Review
2/21/2011
Estropipate for Defective Internal Secretion of Ovaries
3
Patient Review
4/17/2011
Estropipate for Low Estrogen After Operation to Remove Ovaries
2
Patient Review
11/26/2015
Estropipate for "Change of Life" Signs
1.7
Patient Review
9/10/2011
Estropipate for "Change of Life" Signs
Patient Q&A Section about estropipate
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is estropipate still available?
"The drug estropipate is no longer available in the United States."
Answered by AI
Is estradiol the same as estropipate?
"Activella can help to relieve menopausal symptoms, lower your risk of developing osteoporosis and also help with any low estrogen levels. Ogen can also help to relieve symptoms associated with menopause as well as help to prevent any bone loss."
Answered by AI
What is estropipate tablets used for?
"Estropipate can help relieve moderate to severe symptoms of menopause such as hot flashes and night sweats."
Answered by AI
What is estropipate 1.5 mg used for?
"Estropipate is a medication used to treat menopause symptoms, prevent osteoporosis, and replace estrogen in women who don't produce enough of it naturally."
Answered by AI